Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACZ885 plus docetaxel vs docetaxel in previously treated advanced NSCLC
CTR20191483Phase 3Completed
- Sponsor
- Novartis
- Start
- Aug 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of canakinumab in non-small cell lung cancer (NSCLC), sponsored by Novartis. Started Aug 2019; status: completed.
02
Drugs
canakinumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20191483.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20191483.